Texas Biomed Unveils Innovative New Approach Methodologies to Speed Up Drug Development

Advancing Drug Development with New Approach Methodologies at Texas Biomed

In a groundbreaking move for biomedical research, the Texas Biomedical Research Institute is pioneering new tools known as New Approach Methodologies (NAMs). These methodologies are set to significantly enhance the speed and effectiveness of drug discovery and development, all while ensuring the safety of new medicines for human use.

According to Dr. Larry Schlesinger, President and CEO of Texas Biomed, NAMs incorporate advanced techniques that leverage modern technology to provide insights into disease mechanisms and therapeutic efficacy. These tools include artificial intelligence (AI) based computer modeling, sophisticated cell cultures, and microphysiological systems, which primarily utilize human tissues and cells for research.

Understanding the importance of NAMs, Schlesinger states, “These tools, developed over decades, are now making exciting progress, helping to answer critical questions about human health and testing new drugs and therapies.” The potential of NAMs lies in their ability to minimize reliance on traditional, animal-based models, which often fall short in replicating human biological responses.

NAMs are categorized into three main areas: organoids, organ-on-a-chip systems, and machine learning/AI. Organoids are three-dimensional cell structures that mimic human tissues or organs, providing a platform to study diseases. Organ-on-a-chip systems, or microphysiological systems (MPS), simulate the dynamics of human organs, facilitating a deeper understanding of cell interactions and fluid dynamics. Meanwhile, machine learning and AI algorithms promise to enhance the prediction and modeling of treatment outcomes and drug interactions.

Texas Biomed has been at the forefront of NAM research, collaborating with institutions nationwide to develop innovative models. Their efforts include the creation of brain organoids for epilepsy research, intestinal organoids for antiviral drug testing, and placental organoids to investigate fetal development.

One of the standout innovations from Dr. Schlesinger's lab is the technique to generate specialized lung cells using a routine blood draw. This method allows researchers access to alveolar macrophage-like cells, which are challenging to acquire directly from patients. By merging this technology with lung-on-a-chip systems, the institute aims to accelerate studies on respiratory diseases, including influenza, tuberculosis, and age-related disorders.

Texas Biomed has also positioned itself to address serious global health threats by researching pathogens like Ebola and Marburg viruses, thanks to its high-containment research facilities. This capability enables researchers to develop, test, and refine NAMs in a controlled environment, prioritizing public health safety.

Furthermore, Texas Biomed hosts the Southwest National Primate Research Center (SNPRC), one of seven centers dedicated to the ethical study of nonhuman primates. These primates serve as the gold standard for preclinical studies, providing vital information on how new therapies or vaccines perform within a complete immune system before entering human trials. The SNPRC is actively working on establishing biological standards for NAMs, focusing on how these methodologies can accurately demonstrate the safety and efficacy of new treatments compared to conventional animal models.

While the emergence of NAMs represents a promising shift in biomedical research, questions remain regarding their ability to fully replicate the complexities of a human immune system. Dr. Schlesinger acknowledges this limitation, stating, “While NAMs can potentially reduce the number of animals used in essential safety studies, an integrated approach that utilizes both NAMs and animal models is likely to be necessary in the foreseeable future.”

As Texas Biomed forges ahead with innovative NAMs, the biomedical field anticipates significant advancements in treatment safety and efficacy, ultimately benefiting public health. For those interested in the evolution of biomedical methodologies and their implications for the future, Texas Biomed remains a leading institution to watch.

For additional details on their research and methodologies, visit Texas Biomed's website.